基础医学与临床2024，Vol.44Issue(8)：1062-1067,6.DOI:10.16352/j.issn.1001-6325.2024.08.1062
肺动脉高压的抗凝治疗:必要性与困境
Anti-coagulation therapy for pulmonary hypertension:necessity and dilemmas
摘要
Abstract
Pulmonary hypertension(PH)is a rare and life-threatening disease.Over past two decades,rapid ad-vancements in treatment techniques have significantly improved the prognosis of two major subgroups of PH entities:pulmonary arterial hypertension(PAH)and chronic thromboembolic pulmonary hypertension(CTEPH).Given the underlying pathological feature of in situ thrombosis of small arteries,anti-coagulation was previously considered to be a supportive therapy for PAH to improve prognosis.However,due to a lack of robust evidence,it is not recommended by the current guidelines.In contrast,lifelong anticoagulation is recommended for CTEPH patients to prevent thrombus recurrence and in situ thrombosis,based on the thromboembolic etiology.Furthermore,with the advent of direct oral anticoagulants,there are now more options for anti-coagulation therapy in PH.Nevertheless,due to the complexity of PH etiology and the heterogeneity of treatment approaches,anti-coagulation management remains challenging.This article reviews and evaluates the current status and safety issue of anti-coagulation therapy for PH patients,providing guidance and insights for clinical practice and research in this field.关键词
肺动脉高压/慢性血栓栓塞性肺动脉高压/抗凝/靶向药/药物相互作用Key words
pulmonary hypertension/chronic thromboembolic pulmonary hypertension/anti-coagulation/targeted drug/drug interactions分类
医药卫生引用本文复制引用
胡崧,华潞,张健..肺动脉高压的抗凝治疗:必要性与困境[J].基础医学与临床,2024,44(8):1062-1067,6.基金项目
北京市自然科学基金(7222143) （7222143）
中央高水平医院临床科研业务费(2022-GSP-GG-9) （2022-GSP-GG-9）
中国医学科学院医学与健康科技创新工程项目(2022-I2M-C&T-B-040) （2022-I2M-C&T-B-040）
中国医学科学院阜外医院深圳医院,国家心血管疾病临床医学研究中心(深圳)自主课题(NCRCSZ-2023-015) （深圳）
